Corrections

India’s health ministry bans pioglitazone, metamizole, and flupentixol-melitracen

BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h1232 (Published 04 March 2015) Cite this as: BMJ 2015;350:h1232

In this News story (BMJ 2013;347:f4366, doi:10.1136/bmj.f4366), we made the following statement: “Flupentixol with melitracen, which is produced by a Danish company and marketed as Deanxit, is banned by the Danish Medical Association . . . Deanxit is also banned in the US, the UK, Ireland, Canada, Japan, and Australia.”

Lundbeck, the makers of Deanxit, would like to point out that the company has never applied for registration for marketing approval of the drug in Denmark; nor in the US, the UK, Ireland, Canada, Japan, or Australia. Consequently, it is untrue to say that the drugs are banned in these countries. We apologise for this error.

Notes

Cite this as: BMJ 2015;350:h1232

View Abstract